0001209191-21-070258.txt : 20211217
0001209191-21-070258.hdr.sgml : 20211217
20211217161514
ACCESSION NUMBER: 0001209191-21-070258
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20211215
FILED AS OF DATE: 20211217
DATE AS OF CHANGE: 20211217
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Patel Chintu
CENTRAL INDEX KEY: 0001737428
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38485
FILM NUMBER: 211501724
MAIL ADDRESS:
STREET 1: C/O AMNEAL PHARMACEUTICALS LLC
STREET 2: 400 CROSSING BOULEVARD
CITY: BRIDGEWATER
STATE: CA
ZIP: 08807
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Amneal Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001723128
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
BUSINESS PHONE: (908) 947-3120
MAIL ADDRESS:
STREET 1: 400 CROSSING BOULEVARD
STREET 2: 3RD FLOOR
CITY: BRIDGEWATER
STATE: NJ
ZIP: 08807
FORMER COMPANY:
FORMER CONFORMED NAME: Atlas Holdings, Inc.
DATE OF NAME CHANGE: 20171117
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-12-15
0
0001723128
Amneal Pharmaceuticals, Inc.
AMRX
0001737428
Patel Chintu
C/O AMNEAL PHARMACEUTICALS, INC.
400 CROSSING BOULEVARD
BRIDGEWATER
NJ
08807
1
1
0
0
Co-CEO
Class A Common Stock
2021-12-15
4
P
0
100000
4.13
A
462566
D
Class A Common Stock
2021-12-16
4
P
0
50000
4.25
A
512566
D
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.06 to $4.18. The reporting person undertakes to provide Amneal Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or of the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.20 to $4.30. The reporting person undertakes to provide the Company, any security holder of the Company, or of the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
/s/ Meredith Cook, Attorney-in-Fact
2021-12-17